 The study is designed to determine the maximum tolerated dose MTD or recommended phase 2 dose RP2D of EGF816 in combination with INC280 and to estimate the preliminary anti-tumor activity of EGF816 in combination with INC280 in patients with advanced non-small cell lung cancer NSCLC with documented EGFR mutation. 